BioSpace - News

NEWSLETTERS
FREE Newsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News

CAREER NETWORK
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
askHR
For Employers

DIVERSITY

HOTBEDS
Regional News
Biotech Bay™
Biotech Beach™
Genetown™
Pharm Country™
BioCapital™
BioMidwest™
Bio NC™
BioForest™
Southern Pharm™
BioCanada East™

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events

RESOURCES
Real Estate
New Business Opportunities

<< Back |

Abbott Japan and Eisai have Cleared the Condition for Approval of Humira(R), a Fully Human Anti-TNF-Alpha Monoclonal Antibody, for Plaque Psoriasis and Psoriasis Arthropica in Terms of the All-Case Surveillance

Tokyo, Apr 23, 2012 (JCN Newswire) - Abbott Japan Co., Ltd. and Eisai Co., Ltd. announced today that they have received notification from Japan's Ministry of Health, Labour and Welfare (MHLW) that the condition for approval of Humira(R) pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [genetical recombination]), a fully human anti-TNF-alpha monoclonal antibody, has been lifted in terms of a drug use results survey (all-case surveillance) for plaque psoriasis and psoriasis arthropica.

In approving plaque psoriasis and psoriasis arthropica as additional indications for Humira in January 2010, the MHLW imposed the following condition: "A post-marketing drug use results survey of all patients receiving Humira must be conducted until data has been collected for a pre-determined number of cases in order to promptly obtain safety and efficacy data for the drug, and appropriate measures must be taken to ensure its proper use."

The MHLW lifted the condition for approval based on a review of safety and efficacy data for Humira submitted to the Ministry in an interim report outlining analysis results of the all-case surveillance of 634 patients with plaque psoriasis and psoriasis arthropica.

Based on evidence obtained through the survey, Abbott Japan and Eisai will continue to ensure, and provide information on, the proper use of Humira as they seek to make further contributions to improve the quality of life of patients.

About Eisai

Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

About Abbott Japan Co., Ltd.

Headquartered in Chicago, Illinois, Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 83,000 people and markets its products in more than 130 countries.

In Japan, approximately 2,800 Abbott employees are devoted to the manufacture, development, distribution, and marketing of pharmaceuticals and medical products, including nutritionals, devices, diagnostics, and products for vision care. Abbott's main offices in Japan are located in Tokyo, Fukui, and Chiba. News releases issued by Abbott Japan and Abbott Headquarters are available at www.abbott.co.jp and www.abbott.com, respectively.

Contact:


Public Relations Department
Eisai Co., Ltd.
Tel: +81-3-3817-5120

Public Affairs Department
Abbott Japan Co., Ltd.
Tel: +81-3-4588-4602

Apr 23, 2012
Source: Eisai
Eisai (TSE: 4523) (U.S: ESALY)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: Clinical Trial Results